Medicine overview
Indications of Halosin
Established Use
Halosin is indicated for the induction and maintenance of general anesthesia in adults and children undergoing surgical procedures. It is administered exclusively by qualified anesthesiologists or anesthesia providers in a hospital or surgical operating room setting equipped for general anesthesia and continuous patient monitoring.
Adjunct / Combination Use
Halosin is commonly used together with nitrous oxide, oxygen, intravenous induction agents, opioids, and neuromuscular blocking agents as part of a balanced general anesthesia technique.
Not for Self-Administration
Halosin is not a self-administered medicine; it has no outpatient or home-use indication and is not dispensed directly to patients.
Composition
Each unit of Halothane is a volatile halogenated inhalational anesthetic liquid, chemically 2-bromo-2-chloro-1,1,1-trifluoroethane, stabilized with thymol as a preservative, for administration via a calibrated anesthesia vaporizer.
Description
Halosin is a potent, non-flammable, volatile halogenated inhalational anesthetic agent used by trained anesthesia personnel to induce and maintain general anesthesia during surgical procedures. It has a comparatively pleasant, non-pungent odor, which historically made it a preferred agent for inhalation induction, particularly in children. Halosin is administered only through a calibrated vaporizer as part of a general anesthesia machine circuit in a hospital or surgical facility with continuous monitoring.
Therapeutic Class
Halosin belongs to the therapeutic class of general anesthetics, specifically the halogenated volatile (inhalational) anesthetic agents.
Pharmacology
The precise mechanism by which Halothane produces general anesthesia is not fully understood. Like other volatile anesthetics, Halothane is thought to act on the central nervous system by enhancing inhibitory neurotransmission (through potentiation of GABA-A and glycine receptor-mediated chloride currents) and by inhibiting excitatory neurotransmission (including nicotinic acetylcholine and NMDA receptors), producing dose-dependent depression of the central nervous system, loss of consciousness, analgesia, and immobility. Halothane also produces dose-dependent depression of myocardial contractility, vasodilation, and respiratory depression, and sensitizes the myocardium to the arrhythmogenic effects of circulating catecholamines.
Dosage & Administration of Halosin
Administration
Halosin is administered only by inhalation via a specifically calibrated vaporizer connected to an anesthesia machine, delivered in oxygen or an oxygen-nitrous oxide mixture. It must be administered only by an anesthesiologist or anesthesia provider trained in its use, with continuous monitoring of vital signs, oxygenation, and anesthetic depth.
Dosage by Indication
| Use | Typical Concentration | Notes |
|---|---|---|
| Induction of anesthesia | Up to 3-4% in oxygen or oxygen/nitrous oxide, gradually increased from a low starting concentration | Adults and children; concentration titrated to response |
| Maintenance of anesthesia | 0.5-1.5% | Adjusted to maintain adequate depth of anesthesia |
The minimum alveolar concentration (MAC) of Halosin is approximately 0.75% in oxygen, decreasing when combined with nitrous oxide or other adjunct agents. Doses are individualized by the anesthesia provider based on age, body weight, cardiovascular status, and concurrent medications.
Administration of Halosin
Halosin is administered exclusively by inhalation through a calibrated vaporizer as part of a general anesthesia breathing circuit in a hospital or surgical operating room. It is never self-administered or taken by mouth.
Interaction of Halosin
Catecholamines (e.g., Epinephrine)
Halosin sensitizes the myocardium to circulating catecholamines, increasing the risk of serious cardiac arrhythmias when epinephrine or similar agents are administered concurrently; the dose and concentration of epinephrine used during Halosin anesthesia should be limited.
Neuromuscular Blocking Agents
Halosin potentiates the effect of non-depolarizing neuromuscular blocking agents, and doses of these agents may need to be reduced.
CNS Depressants and Opioids
Concurrent use of opioids, benzodiazepines, or other CNS depressants reduces the minimum alveolar concentration (MAC) of Halosin required for anesthesia and may increase cardiorespiratory depression.
Aminophylline / Theophylline
Concurrent use with aminophylline or theophylline has been associated with an increased risk of cardiac arrhythmias during Halosin anesthesia.
Other Hepatotoxic Agents
Concurrent or recent use of other hepatotoxic drugs, or repeated exposure to Halosin itself within a short interval, may increase the risk of hepatotoxicity. See Precautions and Warnings.
Contraindications
- Known hypersensitivity to Halothane or other halogenated anesthetic agents.
- History of unexplained jaundice, hepatic dysfunction, or fever following previous exposure to Halothane (suspected halothane hepatitis).
- Known or suspected susceptibility to malignant hyperthermia (personal or family history).
Side Effects of Halosin
Common
- Hypotension and dose-dependent myocardial depression
- Bradycardia and cardiac arrhythmias
- Respiratory depression
- Nausea, vomiting, and shivering during recovery
Serious (Rare)
- Halosin hepatitis (severe hepatotoxicity) - see Precautions and Warnings
- Malignant hyperthermia - see Precautions and Warnings
- Severe cardiac arrhythmias, cardiac arrest
Pregnancy & Lactation
Halosin, like other general anesthetics, should be used in pregnancy only when clearly needed, such as for anesthesia during cesarean delivery or other surgery required during pregnancy, and only when the potential benefit justifies the potential risk, as it crosses the placenta and can cause dose-dependent uterine relaxation with an associated risk of increased uterine bleeding. Use during labor and delivery should be limited to low concentrations and short durations under the direct supervision of an experienced anesthesia provider. There is limited information on excretion of Halosin in breast milk; because it is eliminated rapidly from the body after anesthesia, breastfeeding can generally resume once the mother has fully recovered from anesthesia, but a physician should be consulted regarding timing.
Precautions & Warnings
Halosin Hepatitis
Rare but potentially fatal hepatotoxicity (Halosin hepatitis) has been reported, particularly after repeated exposure to Halosin within a short interval, in middle-aged obese individuals, and in females. Postoperative unexplained fever, jaundice, or abnormal liver function should prompt investigation, and repeat use of Halosin should be avoided in patients with such a history (see Contraindications).
Malignant Hyperthermia
Halosin is a known triggering agent for malignant hyperthermia, a rare, life-threatening hypermetabolic reaction. Facilities administering Halosin must have immediate access to dantrolene and a malignant hyperthermia management protocol.
Cardiovascular Effects
Halosin can cause dose-dependent hypotension, bradycardia, and myocardial depression, and sensitizes the heart to catecholamine-induced arrhythmias; it should be used with caution in patients with cardiovascular disease.
Use Only by Trained Personnel
Halosin must be administered only by personnel trained in general anesthesia, with appropriate airway management equipment, resuscitation facilities, and continuous monitoring available.
Overdose Effects of Halosin
Excessive depth of anesthesia with Halosin can cause severe hypotension, bradycardia, respiratory depression, and cardiac arrest. If overdose or excessive anesthetic depth is suspected, the anesthesia provider should immediately discontinue Halosin administration, ensure a patent airway with 100% oxygen and ventilatory support, and provide circulatory support (intravenous fluids, vasopressors) as needed. Emergency resuscitation facilities and personnel must be immediately available whenever Halosin is administered.
Storage Conditions
Store below 25°C, protected from light, in a tightly closed original amber-colored container. Do not use if the liquid appears discolored. Keep out of reach of children, and use only in a properly equipped hospital or surgical anesthesia facility.
Use In Special Populations
Pediatric Use
Halosin has been widely used for inhalation induction of anesthesia in infants and children because of its relatively non-pungent odor, and is generally considered effective for this purpose when administered by trained pediatric anesthesia personnel; dosing is individualized by age and weight.
Geriatric Use
Elderly patients may be more sensitive to the cardiovascular depressant effects of Halosin; lower concentrations and slower induction are generally used, with close hemodynamic monitoring.
Hepatic Impairment
Halosin should be used with caution in patients with pre-existing liver disease and avoided in those with a history of unexplained hepatic dysfunction after prior exposure (see Contraindications).
Renal Impairment
No specific dose adjustment is established for renal impairment; Halosin is used with general caution and monitoring in patients with significant renal disease.
Duration Of Treatment
The duration of Halosin administration is determined entirely by the anesthesia provider based on the length and requirements of the surgical procedure, and is limited to the intraoperative period; it is not intended for repeated or prolonged use outside the surgical setting.
Drug Classes
General anesthetic; halogenated volatile (inhalational) anesthetic agent.
Mode Of Action
Halothane produces general anesthesia primarily through actions on ion channels in the central nervous system, enhancing inhibitory GABA-A and glycine receptor activity while inhibiting excitatory synaptic transmission, resulting in reversible loss of consciousness, analgesia, and skeletal muscle relaxation in a dose-dependent manner.
Pediatric Uses
Halosin has a long history of use for inhalation induction and maintenance of general anesthesia in pediatric patients, including infants, due to its non-irritating odor, which facilitates smoother mask induction compared with more pungent agents. It is administered by trained pediatric anesthesia providers with dosing individualized to age and weight, and with careful monitoring for cardiovascular and respiratory depression, to which children may be sensitive.
Frequently Asked Questions
Q: What is Halosin 1.87 gm/ml Solution for Inhalation used for?
A: Halosin 1.87 gm/ml Solution for Inhalation is a volatile inhalational anesthetic gas used by trained anesthesia providers to induce and maintain general anesthesia during surgical procedures in a hospital or operating room setting. It is not a medicine that patients take on their own.
Q: Is Halosin 1.87 gm/ml Solution for Inhalation safe for children?
A: Halosin 1.87 gm/ml Solution for Inhalation has a long history of use for inhalation induction of anesthesia in children because of its non-irritating odor. It is administered by trained pediatric anesthesia providers with careful dosing and monitoring, as children may be sensitive to its cardiovascular and respiratory effects.
Q: What is Halosin 1.87 gm/ml Solution for Inhalation hepatitis?
A: Halosin 1.87 gm/ml Solution for Inhalation hepatitis is a rare but serious liver injury that can occur after exposure to Halosin 1.87 gm/ml Solution for Inhalation, particularly with repeated exposure within a short time interval. Patients with a history of unexplained jaundice or liver problems after previous Halosin 1.87 gm/ml Solution for Inhalation anesthesia should not receive Halosin 1.87 gm/ml Solution for Inhalation again, as this is an absolute contraindication.
Q: Can Halosin 1.87 gm/ml Solution for Inhalation be used during pregnancy?
A: Halosin 1.87 gm/ml Solution for Inhalation should be used during pregnancy only when clearly needed, such as for surgery that must be performed during pregnancy, because it crosses the placenta and can relax the uterus, potentially increasing bleeding risk. Any use during pregnancy or delivery should be decided and supervised by an experienced anesthesia provider and obstetrician.
Q: What are the serious risks of Halosin 1.87 gm/ml Solution for Inhalation anesthesia?
A: The most serious risks of Halosin 1.87 gm/ml Solution for Inhalation include Halosin 1.87 gm/ml Solution for Inhalation hepatitis (rare liver damage), malignant hyperthermia (a rare, life-threatening hypermetabolic reaction), and cardiac arrhythmias due to sensitization of the heart to catecholamines. These are why Halosin 1.87 gm/ml Solution for Inhalation is administered only by trained personnel with resuscitation equipment immediately available.
Q: Who should not receive Halosin 1.87 gm/ml Solution for Inhalation?
A: Halosin 1.87 gm/ml Solution for Inhalation is contraindicated in people with known hypersensitivity to Halosin 1.87 gm/ml Solution for Inhalation or other halogenated anesthetics, those with a history of unexplained liver problems after previous Halosin 1.87 gm/ml Solution for Inhalation exposure, and those known or suspected to be susceptible to malignant hyperthermia.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
